RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Synthesis, nicotinic acetylcholine receptor binding, in vitro and in vivo pharmacology properties of 3'-(substituted pyridinyl)-deschloroepibatidine analogs
Ondachi, P., Ye, Z., Castro, AH., Luetje, CW., Damaj, MI., Mascarella, S., Navarro, H., & Carroll, F. (2015). Synthesis, nicotinic acetylcholine receptor binding, in vitro and in vivo pharmacology properties of 3'-(substituted pyridinyl)-deschloroepibatidine analogs. Bioorganic and Medicinal Chemistry, 23(17), 5693-5701. https://doi.org/10.1016/j.bmc.2015.07.021
Over the last several years we have synthesized and studied the in vitro and in vivo nAChR pharmacological properties of epibatidine (4) analogs. In this study we report the synthesis, nAChR in vitro and in vivo pharmacological properties of 3'-(substituted pyridinyl)-deschloroepibatidine analogs (5a-e and 6a-e). All of the analogs had high binding affinity for alpha4beta2 *-nAChRs. Several of the analogs were potent antagonists of alpha4beta2-nAChRs in in vitro efficacy tests and were potent antagonists of nicotine-induced antinociception in the mouse tail-flick test. Compound 6b had a Ki=0.13nM in the binding assay, 25- and 46-fold selectivity for the alpha4beta2 *-nAChR relative to the alpha3beta4- and alpha7-nAChR, respectively, in the in vitro efficacy test and an AD50=0.13mug/kg in the tail-flick test. Combined with favorable calculated physiochemical properties compared to varenicline, our findings suggest that 6b should be considered for development as a potential pharmacotherapy for treating nicotine addiction and other CNS disorders
